newsfilter
← Latest News
GlobeNewswire·

Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Advanced MYCHELANGELO™ I trial; Company expects to select recommended dose for expansion and initiate monotherapy and combination expansion cohorts in fourth quarter of 2024Reinforced diverse capabilities of the